ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Epidemiology"

  • Abstract Number: 2568 • ACR Convergence 2023

    First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients

    Michael Chen-Xu1, Daniel Cooper2, Rainer Döffinger2, Dr Rachel Jones3 and Rona Smith2, 1Unviersity of Cambridge, Cambridge, United Kingdom, 2University of Cambridge, Cambridge, United Kingdom, 3Addenbrooke's Hospital, Cambridge, United Kingdom

    Background/Purpose: Primary systemic vasculitis (PSV) patients on immunosuppression are at higher risk of adverse outcomes following COVID-19 infection and often mount suboptimal vaccine responses to…
  • Abstract Number: 0119 • ACR Convergence 2023

    Mortality-related Health Metrics in Systemic Autoimmune Diseases: An Epidemiological Analysis of a Nationwide Register-based Cohort

    Mucong Li1, Chanyuan Wu2, Peng Yin3, Qian Wang4, Dong Xu5, Xiaomei Leng2, Xinping Tian1, Ali Duarte-Garcia6, Mengtao Li1, xiaofeng Zeng4 and Maigeng Zhou3, 1Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Peking Union Medical College Hospital, Beijing, China, 3Chinese Center for Disease Control and Prevention, Beijing, China, 4Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 5Department of Rheumatology, Peking Union Medical College, Beijing, China, 6Mayo Clinic, Rochester, MN

    Background/Purpose: Systemic autoimmune diseases (sAIDs) have become leading contributors to premature death. Meanwhile, regional disparities exist in capacity of rheumatology healthcare services delivery. However, no…
  • Abstract Number: 0200 • ACR Convergence 2023

    Herpes Zoster Prevalence in Patients with Rheumatic Diseases

    Rodrigo J. Castillo-de la Garza1, Jorge A. Esquivel-Valerio2, Emmanuel Campos-Tinajero2, Anahí Carrazco Chapa3, Gisela García Arellano4, Axel A. De Leon-Perez2, Pablo Gamez-Siller2 and Dionicio A. Galarza-Delgado5, 1Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, 3Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 4Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, 5Hospital Universitario UANL, Monterrey, Mexico

    Background/Purpose: Herpes zoster (HZ) is a painful rash that is commonly known as shingles. People that had a primary infection caused by the varicella-zoster virus…
  • Abstract Number: 0513 • ACR Convergence 2023

    Impact of Pregnancy on Sacroiliac Imaging in Women with Axial Spondyloarthritis: Results of the Analysis of the DESIR Cohort

    Elodie Portier1, Maxime Dougados2, Adeline Ruyssen-Witrand3 and Anna Molto4, 1Hôpital Cochin, Paris, France, 2Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, 3Toulouse University Hospital, Toulouse, France, 4HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France

    Background/Purpose: Axial spondyloarthritis (axSpA) is typically characterized by imaging (radiographs or MRI) abnormalities of the sacroiliac joints (SIJ). Also, inflammatory lesions of the SIJ have…
  • Abstract Number: 0845 • ACR Convergence 2023

    The Yield of Repeated Assessments in Chronic Back Pain Patients Suspected of Early Axial Spondyloarthritis: Two-year Data from the SPondyloArthritis Caught Early (SPACE) Cohort

    Mary Lucy marques1, Sofia Ramiro2, Miranda Van Lunteren3, Rosalinde Stal3, Robert BM Landewé4, Marleen van de Sande5, Karen Minde Fagerli6, Inger Jorid Berg6, Maikel van oosterhout7, Sofia Exarchou8, Roberta Ramonda9, Désirée van der Heijde2 and Floris Van Gaalen3, 1Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, 4Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, 5Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, 6Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 7Groene Hart Ziekenhuis, Gouda, Netherlands, 8Lund University, Åkarp, Sweden, 9University of Padova, Department of Rheumatology, Padova, Italy

    Background/Purpose: We have shown in the SPACE cohort that a diagnosis of early axial Spondyloarthritis (axSpA) can be reliably made in patients with chronic back…
  • Abstract Number: 1059 • ACR Convergence 2023

    Identification of Patients with Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Using Medicare Claims Data

    Anne Bass1, Fenglong Xie2, Alexa Meara3, Deanna Jannat-Khah4 and Jeffrey Curtis2, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2University of Alabama at Birmingham, Birmingham, AL, 3The Ohio State University Wexner Medical Center, Columbus, OH, 4Hospital For Special Surgery, New York, NY

    Background/Purpose: Immune checkpoint inhibitor (ICI) associated inflammatory arthritis (ICI-IA) has been suggested to occur in approximately 3-6% of ICI-treated patients with cancer1 but most studies…
  • Abstract Number: 1535 • ACR Convergence 2023

    Epidemiology and Treatment Outcome of ANCA-associated Vasculitis in South Korea: A Nationwide, Population-based Cohort Study

    Ji In Jung1, Jun Won Park2, Song Jihun3, Seulggie Choi2, Sun Jae Park3, Sang Min Park2 and Eun Young Lee4, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 2Seoul National University Hospital, Seoul, South Korea, 3Seoul National University Graduate School, Seoul, South Korea, 4Seoul National University College of Medicine, Seoul, South Korea

    Background/Purpose: Previous studies on AAV have shown that the epidemiology and clinical features of GPA and MPA differ among countries. Considering their high mortality and…
  • Abstract Number: 1819 • ACR Convergence 2023

    Clinical Indications Associated with New Opioid Use for Pain Management in the United Kingdom Using National Primary Care Data

    Max Lyon, Carlos Ramirez Medina, Elinor Davies and Meghna Jani, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Prescription opioids for non-cancer pain in the UK have increased considerably over the past two decades, alongside a rise in associated harms. Despite the…
  • Abstract Number: 2104 • ACR Convergence 2023

    Relationship Between Frailty and Large Joint Symptoms in Rheumatoid Arthritis Patients

    Yasumori Sobue1, Mochihito Suzuki2, yoshifumi Ohashi2, Shuji Asai2 and Shiro Imagama2, 1Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan, 2Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a causative factor in frailty. Large joint symptoms in RA patients may be more strongly associated with physical disability than…
  • Abstract Number: 2406 • ACR Convergence 2023

    Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study

    Mohanad Elfishawi1, Mahmut Kaymakci1, Sara Achenbach2, Cynthia Crowson1, Tanaz Kermani3, Cornelia M. Weyand4, Matthew Koster1 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, Rochester, MN, 3University of California Los Angeles, Los Angeles, CA, 4Mayo Clinic School of Medicine and Stanford University, Rochester, MN

    Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
  • Abstract Number: 2588 • ACR Convergence 2023

    Updated Analyses of Cancer Incidence and Risk Factors in a Large International SLE Cohort

    Sasha Bernatsky1, Rosalind Ramsey-Goldman2, Murray Urowitz3, John G. Hanly4, Caroline Gordon5, Michelle Petri6, Ellen Ginzler7, Daniel Wallace8, Sang-Cheol Bae9, Juanita Romero-Diaz10, Mary Anne Dooley11, Christine Peschken12, David Isenberg13, Anisur Rahman14, Susan Manzi15, Soren Jacobsen16, S. Sam Lim17, Ronald van Vollenhoven18, Ola Nived19, Diane L. Kamen20, Cynthia Aranow21, Jill Buyon22, Guillermo Ruiz-Irastorza23, Francisco Sanchez-Guerrero24, Dafna Gladman25, Paul R. Fortin26, Jennifer LF Lee27, Luck Lukusa27, Graciela S Alarcón28, Joan Merrill29, Kenneth Kalunian30, Manuel Ramos-Casals31, Kristjan Steinsson32, Asad Zoma33, Anca Askanase34, Munther Khamashta35, Ian Bruce36, Murat Inanç37 and Ann Clarke38, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2Northwestern University, Chicago, IL, 3Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, 4Dalhousie University, Halifax, NS, Canada, 5Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 6Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 7SUNY Downstate Health Sciences University, Brooklyn, NY, 8Cedars-Sinai Medical Center, Los Angeles, CA, 9Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, 10Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 11Raleigh Neurology Associates, Chapel Hill, NC, 12University of Manitoba, Winnipeg, MB, Canada, 13University College London, London, United Kingdom, 14Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 15Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, 16Rigshospitalet, Copenhagen, Denmark, 17Emory University, Atlanta, GA, 18Amsterdam University Medical Centers, Amsterdam, Netherlands, 19Department of Rheumatology, Institution of Clinical Sciences, Lund University Hospital, Lund, Sweden, 20Medical University of South Carolina, Charleston, SC, 21Feinstein Institutes for Medical Research, Manhasset, NY, 22NYU Grossman School of Medicine, New York, NY, 23Hospital Universitario Cruces, Barakaldo, Spain, 24University Health Network/Sinai Health system, Toronto, ON, Canada, 25Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 26Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 27RI-MUHC, Montreal, QC, Canada, 28Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL, 29Oklahoma Medical Research Foundation, Oklahoma City, OK, 30University of California San Diego, La Jolla, CA, 31Hospital Clinic, Barcelona, Barcelona, Spain, 32Landspitali University Hospital, Reykjavik, Iceland, 33Lanarkshire Centre for Rheumatology and Hairmyres Hospital, East Kilbride, East Kilbride, United Kingdom, 34Columbia University Medical Center, New York, NY, 35GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, 36University of Manchester, Manchester, United Kingdom, 37Istanbul University, Istanbul, Turkey, 38University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada

    Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…
  • Abstract Number: 0120 • ACR Convergence 2023

    Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study

    Mucong Li1, Chaiquan Li2, Mengzhuo Cao3, Ke Lu2, Chanyuan Wu3, Jiuliang zhao1, Qian Wang4, Xinping Tian1, Xun Tang2, Mengtao Li1, xiaofeng Zeng4 and Pei Gao2, 1Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Peking University, Beijing, China, 3Peking Union Medical College Hospital, Beijing, China, 4Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Systemic lupus erythematosus (SLE) is becoming a public health concern because of increasing disease and economic burdens. Epidemiological information on SLE, especially its incidence…
  • Abstract Number: 0232 • ACR Convergence 2023

    Incident Gout After Recombinant Zoster Vaccination in Adults Aged ≥65 Years in the USA

    Susan dosReis1, Chengchen Zhang1, Alejandro Amill-Rosario1, Abree Johnson1, Haeyoung Lee1, O’Mareen Spence2, Driss Oraichi2, Harry Seifert2, Valentine Franck3, Susan Gamble2 and Huifeng Yun2, 1University of Maryland School of Pharmacy, Baltimore, MD, 2GlaxoSmithKline, Rockville, MD, 3GlaxoSmithKline, Wavre, Belgium

    Background/Purpose: In pre‑licensure clinical trials, numerical differences in gout cases between the recombinant zoster vaccine (RZV) and placebo groups have been observed. However, real-world evidence…
  • Abstract Number: 0543 • ACR Convergence 2023

    Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015

    Hilde Haukeland1, Sigrid Reppe Moe1, Cathrine Brunborg2, Antonela Botea3, Nenad Damjanic4, Gro Wivestad5, Heidi Øvreås6, Thea Bøe7, Torhild Garen1, Anniken Orre8, Helga Sanner9, Øyvind Molberg10 and Karoline Lerang9, 1Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 2Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 3Betanien Hospital, Department of Rheumatology, Skien, Norway, 4Ostfold Hospital Trust, Department of Rheumatology,, Grålum, Norway, 5Hospital of Southern Norway Trust, Division of Rheumatology, Department of Medicine, Kristiansand, Norway, 6Lillehammer Hospital for Rheumatic Diseases, Department of Rheumatology, Lillehammer, Norway, 7Vestfold Hospital Trust, Department of Internal Medicine, Tønsberg, Norway, 8Vestre Viken Hospital Trust, Department of Rheumatology, Drammen, Norway, 9Oslo University Hospital, Department of Rheumatology, Nydalen, Norway, 10University of Oslo, Institute of Clinical Medicine, Oslo, Norway

    Background/Purpose: To diagnose Systemic Lupus Erythematosus (SLE), one must understand the phenotype specter and interpret clinical, serological, radiological, and histopathological data, as well as exclude…
  • Abstract Number: 0968 • ACR Convergence 2023

    Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

    Yumeko Kawano1, Dana Weisenfeld1, Qing Liu1, Mary Jeffway1, Gregory McDermott1, Kumar Dahal1, Jennifer Stuart1, Jacob Joseph2, Tianrun Cai1, Brittany Weber1, Tianxi Cai3 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Veteran's Affairs Boston Healthcare System, Boston, MA, 3Harvard T.H. Chan School of Public Health, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) disease including heart failure (HF). HF is a heterogeneous condition that is…
  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 55
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology